REPO-TRIAl Project. (5/31/18). "Press Release: REPO-TRIAL – a European Union Project for In Silico Trial-Based Drug Repurposing". Maastricht.

	Region	EU (European Union)
	Organisation	REPO-TRIAL project (EU, FP8, 201802–202301, In Silico Trial-based Drug Repositioning, €5.6m)
	Organisation 2	H.M. Pharma Consultancy [Hermann Mucke Pharma Consultancy e.U.]
	Product	drug repositioning services
	Product 2	business development (state/region)
	Index term	REPO-TRIAL project–EU (govt): grant, 201802–202301 Horizon 2020 grant €5.6m for in silico trial-based drug repositioning
	Index term 2	REPO-TRIAL project–Biocrates: drug respositioning, 201802–202301 collab Biocrates is industry member of Horizon 2020 project

REPO-TRIAL, a 5-year H2020 project funded by a EUR 5.6 million research grant from the European Commission, is gearing up for a huge push towards accelerated rational drug repurposing by using a consistent systems medicine approach combined with advanced in silico discovery technologies. The project commenced on February 1, and is scheduled to conclude on January 31, 2023.

Systems medicine creates an entirely new perspective for pharmaceutical innovation by conceiving the human body not as a modular collection of organs that require separate treatment, but rather as a highly connected network of molecular regulatory pathways. Drug repurposing, a strategy that is enjoying increasing popularity because it provides a quicker and cheaper route to new treatment opportunities, attempts to re-develop known active pharmaceutical ingredients for therapeutic applications that are fundamentally different from the originally envisaged ones.

“The approach that we are testing in REPO-TRIAL has the potential to disrupt medicine and drug development as we know it,” stated REPO-TRIAL project coordinator Professor Harald Schmidt, chair of the Department of Pharmacology and Personalised Medicine at Maastricht University in the Netherlands. “It will allow us to identify opportunities for approved drugs, and also low-dose combinations of such drugs, and to rapidly advance to pilot clinical trials, with minimal requirements for animal experiments. While our focus will be on neurology and cardiology, especially stroke and heart failure, REPO-TRIAL will also look at other areas of high unmet medical need.”

In addition to its ambitious scientific and development goals, REPO-TRIAL is a shining example of collaboration between academia and industry in Europe. Participants include pharmacology and immunology departments from the universities at Maastricht and Utrecht (The Netherlands), the university clinics at Essen and Hannover (Germany), and the bioinformatics departments at Newcastle University (United Kingdom) and the Technical University at Munich (Germany); while industry participants (SomaLogic, United Kingdom), Biocrates (Austria), and H.M. Pharma Consultancy (Austria) will provide invaluable expertise in the fields of biomarkers, patenting, and public dissemination of results.

For addition details please visit the REPO-TRIAL website at http://www.repo-trial.eu.

Interviews with the project coordinator, Prof. Harald Schmidt, can be arranged through the project administrative management office (see below).

Contact:
Magdalena Kosch, concentris research management GmbH
+49 (0)8141 625 285 80
Email: magdalena.kosch@concentris.de

*** ENDS ***

Record changed: 2023-06-05

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)